Sunscreen is NOT enough: Patient engagement with technology for Pattern Management and Therapeutic Adjustments

> Debbie Hinnen APN, BC-ADM, CDCES, FAAN Advanced Practice Nurse and Certified Diabetes Care and Education Specialist <u>dh@sugar3rn.com</u>

5 Steps to Develop Meaningful Action Plans



Collaboration

- People are the experts in their own lives
- Professionals are the experts in clinical aspects of diabetes
- 99% of diabetes care is *self care*
- Behavior change takes place as health professionals help people make informed decisions about their **self** care.
- Not all patients will be primary decision makers in their own care.

Making a Difference with your Communication What will my patient hear? "We've got to go"

- Verbal/Voice and Tone (38%)
 - Open ended questions
 - Friendly tone
- Nonverbal/Body Language (55%)
 - Open stance, lean forward, no crossed arms
 - Eye contact
- Words (7%)
 - Easy to understand and easy to remember
 - "We've got to go"

Tipping Points

- Depression
- "No Big Deal"
- Inevitability
- Treatment Skepticism
- Unrealistic Plans for Action
- Poor Social Support
- Environmental Pressures

To help Assess Tipping Points....

- No big Deal-Inevitability
 - What worries you about having diabetes?
- Treatment skepticism
 - Help the person see that their regimen is working....How does exercise affect your BG? Check blood sugars before and after starting GLP
- Unrealistic plans
 - Help pts select smaller achievable actions

To Help Assess.....

- Poor Social Support
 - Who could you ask "for help",
 - "to be your walking partner"?
 - What would you say?
- Environmental Pressures
 - Financial, Competing Demands,
 - It is *Hard* to change habits. Move your trash can....
 - What can you change in your environment that might make this easier for you?

DOMINANCE

Behavior Styles

Quickest Determination is to mirror your patient

INFLUENCE



To Get Good Outcomes....

- The D needs to set their own goals/deadlines. They may take on too much
- The I needs deadlines and accountability. Help them get to the goal/point
- The C will analyze for years....Set deadlines
- The S needs to care for themselves and know they are important. Give them permission to be the priority

5 Levels of Motivation Using What, Why & How questions to identify significance.



Educating to Empower

- Set the Goals and Give the Power to the PWD
 - Your A1C goal is <7%. I will help you get the information and skills to help you be independent.
- Self Care Skills: Verify knowledge and basic skills
 - Medication administration
 - Basic eating guidelines
 - Hypoglycemia: symptoms and treatment
 - SMBG and Goals
 - When to call the Dr. and,
 - Sick Days
 - What would you prioritize in a 10 minute 1st visit?

Strategies to Empower

- Identify Learning style. ex: If you set the demo pen on the desk.....
 - Feeler: How does this apply to me?
 - Watcher: Show me
 - Thinker: I will read the instruction manual
 - Doer: Let me just figure it out
- Ask "How do you learn best"?
 - Partner up. Person with biggest jewelry is the Clinician
 - In 1 minute.... Determine learning style

Strategies to Empower

- Employ Adult Teaching Principles
 - Use experiential-hands on tactics
 - Assess readiness to learn...Start there
 - Base info on what the learner already knows
 - Reinforce info and skills
 - Help clarify THEIR management goals
 - With your partner, use your pen/pencil to teach how to give a weekly GLP injection. (Semaglutide, Dulaglutide or Tirzepatide) 2 minutes

Coaching.....

- "Mrs Jackson, I would like to have your thoughts when we review your blood sugar records at your next visit.
- Would you bring your log book with the fastings and after meal blood sugars written down on this form?" AND would you write down notes about what you observed from doing the blood sugars?
 - Verbal Contracting

Asking for input.....

- Mrs S, recent research shows high lipids and diabetes out of control speed up cardiac complications. I don't want you to have a heart attack. I suggest we consider specific steps to reduce your risk factors. Are you willing?
 - Setting a plan with specific/doable steps
- "Mr B, you said you wanted to get your A1c below 8. I agree. We definitely don't want you to have the neuropathy get worse. What is your toughest challenge? What can I do to help make things work better for you?"
 - *Treatment commitment/overcoming barriers*

To Promote Behavior Change

- What part of diabetes is most difficult for you?
- How does that (situation) make you feel?
- How would this have to change to make you feel better about it?
- Are you willing to take action to improve the situation for yourself?
- What are some steps you could take to get you there?
- Is there one thing you will do when you leave here to improve things for yourself?
 - Switch roles with your partner. *The person with T2DM for 10 years has an LDL of 120 and needs to start a statin.* **Be persuasive**

Trouble shooting and Getting a Commitment....

- What questions would you like to ask about the new medicine?
- What will get in the way of you being able to take this?
- On a scale of 1-10 how confident are you that you can do this? (anything below 7-8 unlikely to be successful)
 - What would it take to make your answer a 7 instead of a 6?

Clinical Inertia Sabotages Best Outcomes

- Defined as..."failure to intensify therapy when indicated"¹
- People with Diabetes (PWD) failing to see themselves as partners in their own care¹
- Worsened by...lack of meaningful data to take action in changing therapies or self-care behaviors¹
- Poor self management behavior increase therapeutic clinical inertia²
- Pattern management is an important strategy to combat clinical initial and promote self-management²



6 steps for a accurate test









Lancets vs Drums

Lancets



Pattern Recognition and Principles of Insulin Dose Adjustment



- SMBG schedules shown are for troubleshooting problematic glycemia—not for routine use in patients with stable glycemic control¹⁻⁴ ۲
- There is no consensus on the optimal monitoring schedule for patients using basal insulin without prandial insulin¹⁻⁴
- Very frequent monitoring is burdensome for patients—consider CGM instead of SMBG for these patients²

1. Klonoff DC, et al. J Diabetes Sci Technol. 2011;5:1529-1548; 2. Hinnen D, Tomky D. In: Mensing C, et al, eds. The Art and Science of Diabetes Self-Management Desk Reference. 2nd Ed. Arlington, VA: ADA; 2011:531-575; 3. Accu-Chek. https://www.accu-chek.com/apps-and-software/360-viewtool/support; 4. Practical Insulin. 3rd ed. Arlington, VA: ADA; 2011:1-68.

Х

Χ

How Often and When to test?

- Testing Patterns
 - Testing in pairs:
 - Before Br & 2 hrs after
 - Skip a day
 - Before Lu & 2 hrs after
 - Skip a day
 - Before dinner & 2 hrs after

Year		Brea	kfist			La	nab			Dir	iner		Bed	time	Common
Month	fantes Alter Tran	Cartine 1	<u>1988</u>	199	111	Care	inautine Rissa	191	112	Cards	teath Tean	193	111		
1															
2			-												
0															
-4			-												
- 6															
6															
7															
4															
2															
10															
11															
12															
10															
14															
15															
16															
- 97															
- 10															
- 59															
20															
21															
22															
23															
- 24															
201															
- 26															
27															
- 28															
29															
30															
91															

Phone:

- relevant (" red 1, in (" limit, et al. 1, in () are served as a minimum of the service and the service of the service of

BLOOD GLUCOSE RECORD

							BLOOD	GLUC	OSE GOA	LS:
Patient Name:							Fasting			
							1 hour a	after me	al	
Date of Birth	ate of Birth Phone#								neal	
						Before r	neal			
Email Address	3									
Check your Phy	sician/P	rovider:		Richa	rd Guthr	ie, MD		Belin	ida Childs, A	RNP
					nallans, iah Nels	MD on, MD		Dian	a Guthrie, A a Guthrie, A	RNP
								Debt	bie Hinnen, A	ARNP
		Brea	kfast	Lur	nch	Din	ner		Exercise	6 t-
	Data	hoforo	2 hrs after	hoforo	2 hrs	hoforo	2 hrs after	bed	time	Comments
	Date.	Delote	anco	Delote	arter	Delote	anci	ume		
Blood Glucose										
Medication										
Blood Glucose										
Medication										
Blood Glucose										
Medication										
Blood Glucose										
Medication										
Blood Glucose										
Medication										
Blood Glucose										
Medication										
Blood Glucose										
Medication										
Nurse Email: nurse@madiabe	tesa.com	1		Mi 853	d-America 3 E 32nd 3	a Diabetes St North, V	Associate /ichita, KS	s, PA 67226		Phone: (316)687-310 Fax: (316)687-444

Pattern Management Process

Step 1 Identify the glycemic abnormality

-Look at 3+ days of glucose data

- Priority 1 Hypoglycemia
- Priority 2 Fasting Hyperglycemia
- Priority 3 Postprandial Hyperglycemia*

Step 2 Determine timing and frequency of occurrence

Step 3 Investigate potential causes

Step 4 Take action

*Results greater than 50 mg/dL higher than preprandial need attention

Hinnen D and DeGroot J. Therapy Intensification: Pattern Management and Technology in Art and Science of Diabetes Care and Education. 2023.

Step 1 – Identify the Glycemic Abnormality *Priority 1 – Hypoglycemia*



Priority 2. Fix the fastings (>110 mg/dL)



**American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control. 2002.

Priority 3 Postprandial hyperglycemia



What Do You See? *Case Study: Marv*



What Do You See? Is there a pattern? Case Study: Ma Accu-CHEK * 360° View Blood Glucose Analysis System

- Situation: High after meals
- Medications: Metformin, 1000 mg 2x/d

A1C: 9.2%

- Although fastings are a little high, the main problem is elevated after meals. Breakfast shows very large excursions, but lunch & supper are also c beyond the 50 mg/dL excursion cutpoint.
- Possible Tx Changes:
- Start on GLP-1RA or GLP/GIP?
 - DPP4?
- SGLT2 inhibitor
- Basal insulin?



accu-chek.com © 2011 Roche WARNING

American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control. 200

31 | Achieving A1C results through structured self-monitoring of blood glucose (SMBC

What Do You See? Case Study: Bobby

	Day	1	Date	71	21		1	Day	2	Date	3/	22		_	Day	3	Date	2	12.	3	14]	$\Lambda 1C = 0.4\%$
	Before breakdast	2 hours after breakfast	Before hunch	2 hours after hunch	Before dinner	2 hours after dinner	Before bed	Before breakfast	2 hours after breakfast	Before	2 hours after funch	Before dinner	2 hours after dinner	Before	Before breakfast	2 hours after breakfast	Before lunch	2 hours after hunch	Before dinner	2 hours after dinner	Before		ATC = 9.4 /0
Tine Veal Size S M L	7:00	9.00 Om 1	12	2:00	6'a	8.15 5 NC	11.00	7,00	9.15 O	12	2.0	6:15	8:15	//:.00	6210	9:30	12	2:00	7:00	9:00	11:0		Mean bG = 221
Energy Level* Blead Glucose	206	238	101	259	139	275	277	12015	236	12345	219	101	294	291	1	26)	1011	1201	185	203	192		
2000 1000	×	×	X	X	\checkmark	*	*	×	X		*	-	*	*		×	X	*	*	×	*	Alter- Meul Goal ¢-1 Facting/ Before- Meet Goal	Sulfonylurea 10 mg BID TZD 30 mg DPP-4 inhibito 100 mg
What is your energy level?	1 Very Lo	ENER 2 w Some Lo	GY LE	VEL 3 deratal Sic	A mewhat High	5 Wery High	What M	at did y lys ate	you lear suga out	n from	ave ave	this an	alysis o chi chi chi	sh lee	blood beca	glucose UCC OX C	T e	si zt ce					

What Do You See? Case Study: Bo

Situation: Patient is on several oral

agents, not at goal

- Medications:
 - Glipizide, 10 mg 2x daily
 - Actos (Pioglitazone), 15 mg 1x daily
 - Januvia, 100 mg 1x daily
- Bobby recognizes that lifestyle changes (eating, exercise) are needed.
- Possible Tx Changes
 - Discontinue glipizide and Januvia; start
 - on GLP or GLP/GIP or Lantus 10u ?
 - Start metformin XR 500 mg 2x daily
 - Lifestyle counseling (diet, exercise)



SELF MANAGEMENT RECORD



Reaction M-mild 1 increased activity A address the -

Finger stick Testing Does Not Show the Whole Picture



DexCom. Data on file. San Diego, Calif.

Continuous Glucose Monitoring

CGM Catches Glycemic Excursions that BGM May Miss^{1,2}

CGM Systems Replace BGM



Continuous Glucose Sensors: What Are The Options?



https://consumerguide.diabetes.org/collections/cgm 2024

Fifteen-day glucose traces of two patients with identical AIC of 8.0%²





GLUCOSE STATISTICS AND TARGETS		TIME	N RANGES
26 Feb 2019–10 Mar 2019 % Time CGM is Active	13 days 99.9%		Very High (>250 mg/dL)
Glucose Ranges Targets [% of 1 Target Range 70–180 mg/dLGreater than 70 Below 70 mg/dLGreater than 4% (Below 54 mg/dL Less than 1% (Readings (Time/Day)] 0% (16h 48min) 58min) 14min)	250	High (181–250 mg/dL) 23% (5h 31 min)
Above 180 mg/dL Less than 25% Above 250 mg/dL Less than 5% (Each 5% increase in time in range (70–180 mg/dL) is	(6h) 1h 12min) clinically beneficial.		Target Range (70-180 mg/dL) 47% (11h 17mi)
Average Glucose Glucose Management Indicator (GMI) Glucose Variability	173 mg/dL 7.6% 49.5%	70 54	Low (54–69 mg/dL)

Name MRN

AMBULATORY GLUCOSE PROFILE (AGP)

AGP is a summary of glucose values from the report period, with median (50%) and other percentiles shown as if occurring in a single day.



DAILY GLUCOSE PROFILES



Each daily profile represents a midnight-to-midnight period.

PATTERN MANAGEMENT WITH THE AGP:AMBULATORY GLUCOSE PROFILE



Curves/plots represent glucose frequency distributions by time regardless of date



Daily Glucose Summary





Carlson AL, Mullen DM, Bergenstal RM. Clinical use of continuous glucose monitoring in adults with type 2 diabetes. *Diabetes Technol Ther*. 2017;19(Suppl. 2):S4–S11.

AGP Report

October 18, 2021 - October 31, 2021 (14 Days)

•

LibreView

7% (1h 41min)

22% (5h 17min)

61% (14h 38min)

7% (1h 41min)

3% (43min)

October 18, 2021 - October 31, 2021 % Time CGM is Active	14 Days 93%		. Very High >250 mg/dL
Ranges And Targets For	Type 1 or Type 2 Diabetes	250	
Glucose Ranges Target Range 70-180 mg/dL	Targets % of Readings (Time/Day) Greater than 70% (16h 48min)	180	High 181 - 250 mg/dL
Below 70 mg/dL	Less than 4% (58min)		
Below 54 mg/dL	Less than 1% (14min)		
Above 180 mg/dL	Less than 25% (6h)		Target Range 70 - 180 mg/c
Above 250 mg/dL	Less than 5% (1h 12min)		
Each 5% increase in time in range (70-180 mg/dL)	is clinically beneficial.		
verage Glucose	147 mg/dL	70	Low 54 - 69 mg/dL
Slucose Management Indicator (GM) 6.8%	54	·····
Slucose Variability	42 2%		- Very Low <54 mg/dL

٠

Defined as percent coefficient of variation (%CV); target ≤36%

Glucose







Time in Target Recommendations



research is needed. Please see Pregnancy section in text for more considerations on targets for these groups.

* Includes percentage of values >250 mg/dL (13.9 mmol/L).

** Includes percentage of values <54 mg/dL (3.0 mmol/L).

Current Research Supports Patient Titration of insulin...



1.At Lantus; 2. PREDICTIVE 303; Helwick C and Meneghini L. Nov 2007; 3 Initiate Plus; 4. Autonomy: Edelman S, Liu R, Johnson J, and Glass L. **Diabetes Care,** Aug 2014; 5.Rodbard H et al. Lancet Diabetes & Endocin. Vol 2, Jan 2014

Recognizing the Need for Uptitration From Glucose Records

Blood Glucose Graph

Handwritten SMBG Diary

CGM Output 300 Time BG ----Mon -----Wed Date 300 250 Mon 6:00 AM 157 250 200 Blood Glucose, mg/dL 100 240 6:00 PM Blood Glucose, mg/dl 120 100 4:40 AM 145 Tue **Target Glucose Range** Target Glucose Range 192 7:20 AM 12:45 PM 210 50 Mean -SD 50 10:20 PM 187 000 010 040 060 080 100 120 140 160 1300 100 120 Weds 0 6:00 AM 152 **Breakfast** Lunch Dinner **Bedtime**

All blood glucose measurements, before and after meals, are above target

How to Use Pattern Management to Adjust Basal Insulin

Pattern Observed ¹⁻⁵	Action to Take ¹⁻⁵
All readings above targets	Increase basal dose
PPG readings above targets	 Add GLP-1 RA, SGLT2i, or DPP-4i Add/increase prandial insulin dose
Hypoglycemia	Decrease basal dose
Frequent, unpredictable glycemic fluctuations	 Investigate lifestyle, activity, and alcohol habits Evaluate meal/carbohydrate intake Look for hypertrophies May be a pump candidate
Early morning glucose levels are not at target	Increase/decrease bedtime basal dose accordingly
	 Klonoff DC, et al. J Diabetes Sci Technol. 2011;5:1529-1548; 2. Hinnen D, Tomky D. In: Mensing C, et al, eds. The Art and Science of Diabetes Self-Management Desk Reference. Arlington, VA: ADA; 2011:531-575; 3. Accu-Chek. https://www.accu-chek.com/apps-and-software/360-view- tool/support; 4. Practical Insulin. Arlington, VA: ADA; 2011:1-68.

Simple pumps focused on T2D



CeQur Simplicity Patch pump delivers RAI in 2u increments.



V-Go Patch pump. Zealand 56, 66, 76 total u/ 24hr use

OmniPod 5 Tubless patch pump with sensor

AUTOMATED INSULIN PUMPS



Tandem X2 **Control IQ**

Pump and sensor with screen like smart

88

..........

phone

iLet by BetaBionics Pump and sensor. Set up based on wt.





Uses Guardian 3 or 4 sensor Can bolus q 5m. Detects missed/miscalculated carbs.



Tandem Mobi Based on Control IQ technology

https://consumerguide.diabetes.org/collections/pumps 8-2024

HYPOGLYCEMIA IS A COMMON COMPLICATION OF DIABETES MANAGEMENT

- □ **Most people** with T1D experience hypoglycemia^{1,2}
- □ **30% to 40%** of people with T1D experience **1-3 severe** hypoglycemia events per year³
- **50 %** of people with T2 Diabetes experience hypoglycemia⁴
- I in 5 people with T2D experience ≥1 severe hypoglycemic event per year⁵

T1D, Type 1 diabetes; T2D, Type 2 diabetes

- 1. Spanakis EK et al. NCBI Bookshelf. 2018.
- 2. Cryer PE. *Diabetes.* 2008;57:3169-3176.
- 3. International Hypoglycaemia Study Group. *Diabetes Care.* 2015; 38: 1583-1591.
- 4. Gehlaut RR et al. J Diabetes Sci and Technol. 2015;9(5):999-1005.
- 5. Edrige CL et al. PLOS One. 2015.

SEVERE HYPOGLYCEMIA OCCURS AT ALL LEVELS OF GLYCEMIC CONTROL AND ALL AGES

% Persons With Type 1 Diabetes Experiencing ≥1 Severe Hypoglycemic Event^a In Prior 3 Months By Recent HbA1C (N=11,060)^b The risk of severe hypoglycemia increases with age

HbA1C-recent	6-12 years old N=1313	13-17 years old N=3183	18-25 years old N=2445	26-49 years old N=2143	>50 years old N=1976
<7%	4%	5%	4%	6%	10%
7.0-7.5%	3%	3%	4%	5%	11%
7.5-8%	4%	4%	4%	7%	8%
8-9%	5%	4%	6%	7%	9%
>9%	7%	6%	7%	14%	9%

^aSevere hypoglycemic event defined by loss of consciousness or seizure.

^bManagement practices and health outcomes were reported for 22,697 patients (ages 1 to 93 years) enrolled in the T1D Exchange Registry from 2016 to 2018. Foster NC et al. *Diabetes Technol & Ther.* 2019;21(2):66-72.

Classification of Hypoglycemia

BG ≤ 70 mg

Level 1^{1,2}

- Hypoglycemia alert value
- Treat with fast-acting carbohydrate and insulin dose reduction
- Affects ≈ 50% of patients with T2DM per month who use insulin or secretagogues

BG < 54 mg/dL

Level 2¹

- Clinically significant hypoglycemia
- Indicates clinically important hypoglycemia

Assistance Required

Level 3^{1,3,4}

- Severe hypoglycemia
- No specific glucose threshold
- Associated with severe cognitive impairment requiring external assistance for recovery
- Affects 1%-3% of patients with T2DM per year, regardless of medications used

Hypoglycemia of any degree of severity is *serious*⁵

1. ADA. *Diabetes Care*. 2018;41(suppl 1):S1-S159; 2. Ratzki-Leewing A, et al. *BMJ Open Diabetes Res Care*. 2018;6:e000503; 3. Lipska KJ, et al. *Diabetes Care*. 2017;40:468-475; 4. Karter AJ, et al. *J Diabetes Complications*. 2017;31:869-873; 5. Cryer PE, et al. *J Clin Endocrinol Metab*. 2009;94:709-728.

Physiological Responses to Hypoglycemia

Increasing severity of hypoglycemia									
Blood Glucos	e < 70 mg/dL	Blood Glucose < 50 mg/dL							
Adrenergic	Cholinergic	Neuroglycopenic (early)	Neuroglycopenic (late)						
 Tremulousness Palpitations Anxiety/arousal Sympathoadrenal Pallor Diaphoresis Elevated heart rate Elevated systolic blood pression 	 Sweating Hunger Paresthesia 	 Warmth Weakness Fatigue Confusion Behavioral changes Emotional lability 	 Hypothermia Diplopia Hemiparesis Seizures Loss of consciousness Coma¹ Brain damage 						
Farly signs are absent	in unaware individuals								

Individual symptoms may not match textbook descriptions and may change over time

ADA. *Diabetes Care*. 2018;41(suppl 1):S1-S159. Cryer PE, et al. *Diabetes Care*. 2003;26:1902-1912. Cox DJ, et al. *Diabetes Care*. 1993;16:519-527.

Recognizing Hypoglycemia From Blood Glucose Records

Blood Glucose Graph CGM Output 300 Date Time BG ----Mon -----Wed Mean -SD Target 300 57 250 Mon 6:00 AM 250 6:00 PM 140 200 Blood Glucose, mg/dL Blood Glucose, mg/dl 120 100 4:40 AM 45 Tue 150 Target Glucose Range Target 7:20 AM 92 **Glucose Range** 100 12:45 PM 110 50 50 10:20 PM 87 000 020 040 060 080 100 120 140 160 180 200 200 Weds 6:00 AM 160 0 **Breakfast** Lunch Dinner **Bedtime**

Handwritten SMBG Diary

Some (not necessarily all) blood glucose measurements are below target

Hypoglycemia in CGM Downloads





Hypoglycemia Treatment

-Sweet Bite ...



1C. Milk



1/3-1/2 C. OJ



5-6 lifesavers







4 glucose tabs

- -Eat a Sweet Bite
- -Wait 15 minutes
- -Re-check glucose (goal: >100mg)
- -Re-Treat if needed
- (try holding sweet in your mouth)
- -Then have snack with solid protein
- -Document it
- -Carry a sweet bite with you all the time!

OTHER TREATMENT OPTIONS FOR HYPOGLYCEMIA

4 glucose tabs



....New Glucagon Delivery

- Lilly: Nasal Glucagon (BAQSIMI) 3mg
 - Nasal glucagon, no reconstitution
 - >4y/o
- Xeris, Glucagon injection (G-Voke hypopen)0.5mg and 1mg
 - Re-constituted. pre-filled (PFS) and
 - Hypo pen, Auto injector 2021
- Zeland: Dasiglucagon (Zegalogue), 0.6mg/0.6ml
 - Approved 3-22-21, available 6-21
 - Auto injector and prefilled >6 y/o





Nasal Glucagon





- Nasal powder dosing: delivers into patient's nose by pushing bottom of dispenser
 - Nasal cavity has a large surface area and rich blood supply for absorption
- No need to inhale = consistent dosing
- Found to be non-inferior (works as well) to 1mg injectable glucagon in a cross-over study with 75 participants
 - Mean time to recovery: 16 min (IN) vs 13 min (IM) (P<0.001)
- Studied in patients with nasal congestion: dosing found to be consistent
- Single-use dose 3mg

Nasal Glucagon

- Indicated for severe hypoglycemia in PWD over 4 years old
- Can be carried in high and low temps
- Stable at room temp





www.baqsimi.com

Glucagon Hypo Pen (Gvoke)

- Room temperature stable, non-aqueous liquid form of glucagon
- Proprietary formulation technology (XeriSol[™])
- Long-term stability at room temperature
- Pre-mixed solution in auto-injector
 - Doses: 0.5mg, 1mg
- Phase 2 trials for other indications
 - Post-bariatric hypoglycemia, exercise induced hypoglycemia





Table 6.6—Median monthly (30-day) AWP and NADAC of glucagon formulations in the U.S.

Product	Form(s)	Median AWP* (min, max)	Median NADAC* (min, max)	Dosage(s)
Glucagon	Injection powder with diluent for reconstitution	\$266 (\$194, \$369)	\$249 (\$225, \$273)	1 mg
Glucagon	Nasal powder	\$337	\$270	3 mg
Glucagon	Prefilled pen, prefilled syringe	\$368	\$285	0.5 mg, 1 mg
Dasiglucagon	Prefilled pen, prefilled syringe	\$371	NA	0.6 mg

AWP, average wholesale price; max, maximum; min, minimum; NA, data not available; NADAC, National Average Drug Acquisition Cost. AWP and NADAC prices are as of August 2023. *Calculated per unit (AWP [147] or NADAC [148]; median AWP or NADAC is listed alone when only one product and/or price is described).

Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes - 2024. Diabetes Care 2024;45(Suppl. 1):S111-S125

Hypoglycemia Unawareness

- A major risk factor for severe hypoglycemic episodes involving seizures or coma¹
- Occurs more often than you might expect, in approximately 40% of people with type 1 diabetes, and less often in type 2 diabetes
- Defined as the onset of neuroglycopenia before the appearance of autonomic warning symptoms², or as the failure to sense a significant fall in blood glucose below normal levels³
- HU is multifactorial, possible mechanisms include chronic exposure to low blood glucose, antecedent hypoglycemia, recurrent severe hypoglycemia and the failure of counter-regulatory hormones⁴

1. Jancin, B, Detection and Reversal of Hypoglycemia Unawareness. Fam Prac News. 2006. Feb 2006.

2. de Galan BE, Schouwenberg BJ, Tack CJ, Smits P. Pathophysiology and management of recurrent hypoglycaemia and hypoglycaemia unawareness in diabetes. Neth J Med. 2006;64:269–279

3. Moghissi E, Ismail-Beigi F, Devine RC. Hypoglycemia: minimizing its impact in type 2 diabetes. Endocr Pract. 2013;19:526–535
 4. Martín-Timón I, Javier del Cañizo-Gómez F, <u>World J Diabetes</u>. 2015 Jul 10; 6(7): 912–926 #ADCES2

NPH Requires Extra Precautions to Use Safely



NPH-based insulins require thorough mixing before injection



Failure to resuspend NPH can cause doses that are double or half as much as intended



NPH absorption varies by injection site



With any insulin, HCPs should assess patient's injection technique regularly— errors are common

The peak action of NPH varies from dose to dose



Patients need to *commit in advance* to the next meal in terms of content and timing

1. Lucidi P, et al. *Diabetes Care*. 2015;38:2204-2210; 2. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/; 3. Frid AH, et al. *Mayo Clin Proc*. 2016;91:1231-1255; 4. Trief PM, et al. *Clin Diabetes*. 2016;34:25-33; 5. King L. *Nurs Stand*. 2003;17:45-52; 6. Heise T, et al. *Diabetes*. 2004;53:1614-1620; 7. Hirsch IB, et al. *Clin Diabetes*. 2005;23:78-86.

Patients Miss Doses, Mis-Time and Reduce Insulin to Reduce Hypoglycemia Risk



Ask PWD about Hypoglycemia at Every Office Visit

Consider these questions for your charting template



How many times have you had BG < 70 mg/dL in the past 2 weeks?

How low is your BG when you feel symptoms?

What symptoms let you know that your BG is low? Do they change?

How do you treat low BG?

What do you carry with you *at all times* in case you need to treat low BG?

What do you do to prevent low BG?

1. Seaquist ER, et al. *Diabetes Care*. 2013;36:1384-1395. 2. Unger J. *Diabetes Metab Syndr Obes*. 2011;4:253-261.

Meet Alex

- Alex is a 66 year old male with type 2 diabetes x 10 years, A1C=6.7%, BMI=33kg/m^{2,} Scr=1.5mg/dL, eGFR=42
- Checks glucose 2x daily; FBG: 53-180, Bedtime: 110-175
- Comorbidities: Obesity, Hypertension, CKD
- Medications:
 - Lisinopril 40mg daily
 - Carvedilol 25mg BID
 - Metformin 500mg BID
 - Glipizide 10mg BID
 - Insulin glargine 60 units QPM
 - Atorvastatin 40mg daily
 - Aspirin 81mg ddaily

Alex Case Questions

- Which of these medications could mask the symptoms of hypoglycemia?
- Which medications are most likely to contribute to hypoglycemia?
- What changes would you recommend?
- How would you counsel Alex about hypoglycemia?

Patient Case Questions

- Which of these medications could mask the symptoms of hypoglycemia?
 - Carvedilol Beta Blocker
- Which medications are most likely to contribute to hypoglycemia?
 - Glipizide, especially 6-8 hrs later. Glargine to some degree, ~4 hrs after injection
- What changes would you recommend?
 - Place a CGM for evaluation of hypoglycemia. Hypo unawareness?
 - Check MCare formulary and change to other meds with less hypoglycemic effect, ie, SGLT2, GLP. Stop glipizide (not renal friendly), reduce glargine 50%.
- How would you counsel Alex about hypoglycemia?
 - Signs and symptoms, advise to carry something sweet with him at all times

Summary

- Figure out your patients Behavior Style. Try to mirror that
- Encourage independence through technology and shared decision making
- Hypoglycemia is a serious, life-threatening complication of diabetes treatment.
- Discuss hypoglycemia at every visit by asking questions and reviewing glucose data.
- New technology helps with prevention efforts. Ie, low glucose alerts
- Now glucagon formulations make treatment easier.
- Choose medications with lower hypoglycemia risks.

